FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2096988077> ?p ?o ?g. }

• W2096988077 endingPage "3858" @default.
• W2096988077 startingPage "3853" @default.
• W2096988077 abstract "A promising treatment strategy for stage 4 neuroblastoma patients is the repeated application of anti-GD2 immunotherapy after activating myeloid effectors with granulocyte-macrophage colony-stimulating factor (GM-CSF). To use early marrow response as a prognostic marker is particularly relevant for patients not likely to benefit from this therapy.Eighty-six stage 4 neuroblastoma patients older than 1 year at diagnosis were classified in four clinical groups on protocol entry: complete remission or very good partial remission (n = 33), primary refractory (n = 33), secondary refractory (n = 10), and progressive disease (n = 10). Bone marrow samples collected before and following treatment were assayed for GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction. Response and survival analyses were performed on posttreatment samples before the third cycle at 1.8 months from protocol entry.GD2 synthase mRNA was evident in pretreatment marrow samples of the four clinical groups (42%, 52%, 60%, and 80% of samples, respectively), with median transcript level of 10.0, 16.6, 26.5, and 87.2, respectively. This marker became negative following antibody plus GM-CSF in 77% of complete remission or very good partial remission, 45% of primary refractory, 25% of secondary refractory, and 0% of progressive disease group. Progression-free survival was statistically different between responder and nonresponder groups (P <.0001). Among patients with minimal residual disease, molecular responders had a significantly lower risk of disease progression at a median follow-up of 29.8 months (P =.0001).GD2 synthase mRNA is a sensitive response marker of neuroblastoma in the bone marrow. It is particularly useful for minimal residual disease evaluation and may potentially be useful as an early predictor of resistance to antibody plus GM-CSF immunotherapy." @default.
• W2096988077 created "2016-06-24" @default.
• W2096988077 creator A5034081882 @default.
• W2096988077 creator A5043729995 @default.
• W2096988077 creator A5060645426 @default.
• W2096988077 creator A5083817841 @default.
• W2096988077 date "2003-10-15" @default.
• W2096988077 modified "2023-10-13" @default.
• W2096988077 title "Early Molecular Response of Marrow Disease to Biologic Therapy Is Highly Prognostic in Neuroblastoma" @default.
• W2096988077 cites W1565403166 @default.
• W2096988077 cites W1575002436 @default.
• W2096988077 cites W1821283949 @default.
• W2096988077 cites W1825707388 @default.
• W2096988077 cites W1844660989 @default.
• W2096988077 cites W1901831739 @default.
• W2096988077 cites W1940650862 @default.
• W2096988077 cites W1960710326 @default.
• W2096988077 cites W1972953239 @default.
• W2096988077 cites W1976897003 @default.
• W2096988077 cites W1998347916 @default.
• W2096988077 cites W2007527741 @default.
• W2096988077 cites W2051804704 @default.
• W2096988077 cites W2063286298 @default.
• W2096988077 cites W2080430937 @default.
• W2096988077 cites W2083933004 @default.
• W2096988077 cites W2096398040 @default.
• W2096988077 cites W2122070299 @default.
• W2096988077 cites W2140591503 @default.
• W2096988077 cites W2151069914 @default.
• W2096988077 cites W2159325547 @default.
• W2096988077 cites W2168664911 @default.
• W2096988077 cites W2172587361 @default.
• W2096988077 cites W2280912529 @default.
• W2096988077 cites W2327522594 @default.
• W2096988077 doi "https://doi.org/10.1200/jco.2003.11.077" @default.
• W2096988077 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14551304" @default.
• W2096988077 hasPublicationYear "2003" @default.
• W2096988077 type Work @default.
• W2096988077 sameAs 2096988077 @default.
• W2096988077 citedByCount "48" @default.
• W2096988077 countsByYear W20969880772012 @default.
• W2096988077 countsByYear W20969880772013 @default.
• W2096988077 countsByYear W20969880772014 @default.
• W2096988077 countsByYear W20969880772015 @default.
• W2096988077 countsByYear W20969880772017 @default.
• W2096988077 countsByYear W20969880772019 @default.
• W2096988077 countsByYear W20969880772020 @default.
• W2096988077 countsByYear W20969880772021 @default.
• W2096988077 countsByYear W20969880772022 @default.
• W2096988077 countsByYear W20969880772023 @default.
• W2096988077 crossrefType "journal-article" @default.
• W2096988077 hasAuthorship W2096988077A5034081882 @default.
• W2096988077 hasAuthorship W2096988077A5043729995 @default.
• W2096988077 hasAuthorship W2096988077A5060645426 @default.
• W2096988077 hasAuthorship W2096988077A5083817841 @default.
• W2096988077 hasConcept C121608353 @default.
• W2096988077 hasConcept C126322002 @default.
• W2096988077 hasConcept C142424586 @default.
• W2096988077 hasConcept C143998085 @default.
• W2096988077 hasConcept C146357865 @default.
• W2096988077 hasConcept C151730666 @default.
• W2096988077 hasConcept C203014093 @default.
• W2096988077 hasConcept C2776715637 @default.
• W2096988077 hasConcept C2777701055 @default.
• W2096988077 hasConcept C2778822529 @default.
• W2096988077 hasConcept C2779134260 @default.
• W2096988077 hasConcept C2779282312 @default.
• W2096988077 hasConcept C2779823535 @default.
• W2096988077 hasConcept C2780007613 @default.
• W2096988077 hasConcept C54355233 @default.
• W2096988077 hasConcept C71924100 @default.
• W2096988077 hasConcept C81885089 @default.
• W2096988077 hasConcept C86803240 @default.
• W2096988077 hasConcept C87355193 @default.
• W2096988077 hasConcept C90924648 @default.
• W2096988077 hasConceptScore W2096988077C121608353 @default.
• W2096988077 hasConceptScore W2096988077C126322002 @default.
• W2096988077 hasConceptScore W2096988077C142424586 @default.
• W2096988077 hasConceptScore W2096988077C143998085 @default.
• W2096988077 hasConceptScore W2096988077C146357865 @default.
• W2096988077 hasConceptScore W2096988077C151730666 @default.
• W2096988077 hasConceptScore W2096988077C203014093 @default.
• W2096988077 hasConceptScore W2096988077C2776715637 @default.
• W2096988077 hasConceptScore W2096988077C2777701055 @default.
• W2096988077 hasConceptScore W2096988077C2778822529 @default.
• W2096988077 hasConceptScore W2096988077C2779134260 @default.
• W2096988077 hasConceptScore W2096988077C2779282312 @default.
• W2096988077 hasConceptScore W2096988077C2779823535 @default.
• W2096988077 hasConceptScore W2096988077C2780007613 @default.
• W2096988077 hasConceptScore W2096988077C54355233 @default.
• W2096988077 hasConceptScore W2096988077C71924100 @default.
• W2096988077 hasConceptScore W2096988077C81885089 @default.
• W2096988077 hasConceptScore W2096988077C86803240 @default.
• W2096988077 hasConceptScore W2096988077C87355193 @default.
• W2096988077 hasConceptScore W2096988077C90924648 @default.
• W2096988077 hasIssue "20" @default.
• W2096988077 hasLocation W20969880771 @default.
• W2096988077 hasLocation W20969880772 @default.

• next